The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Curza Inc., a biotechnology company, a $1,000,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855). This funding supports Curza's development of a new class of broad-spectrum antibiotics focused on treating multidrug-resistant (MDR) Gram-negative bacterial infections.
The key objectives of this 3-year project are to optimize the oral bioavailability of Curza's lead CZ-02 antibiotic candidates, conduct in vivo pharmacokinetic and efficacy studies, and prepare a lead compound for potential IND-enabling studies. This work builds upon Curza's prior NIAID-funded research into developing novel antibiotics that selectively inhibit bacterial protein synthesis while minimizing cytotoxic effects on mammalian cells, representing an innovative approach to address antimicrobial resistance. The project is expected to advance a new oral antibiotic candidate targeting Gram-negative pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli.
Generated 2/25/25, 2:54 AM